Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Poseltinib (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions; Therapeutic Use
Acronyms RAjuvenate
Sponsors Eli Lilly and Company

Most Recent Events

07 Apr 2022 This trial has been completed in Slovakia and Spain (End Date: 20 Aug 2018), according to European Clinical Trials Database record.
15 Dec 2020 Results published in The Journal of Rheumatology
15 Jun 2019 Interim results evaluating safety and efficacy of Ly3337641 in patients with rheumatoid arthritis presented at the 20th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com